Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

Multi-center Phase 1/2 study to evaluate safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing – Cannabinoid CB2 receptors are found in many difficult-to-treat cancers, including lung, renal, and ovarian cancers – Inhibiting CB2 receptors has the potential to …

NEXT Oncology Selects proXimityTM to Automate Data Transfer for Clinical Trials

System will accelerate performance evaluation of new drugs in early phase research for cancer patients. (SAN ANTONIO) October 17, 2022 –– NEXT Oncology has selected proXimityTM as the exclusive tool to automate the transfer of clinical trial data from their electronic medical record (EMR) to the electronic data capture (EDC) systems used by sponsor organizations doing clinical trials with NEXT …

Dr. Anthony Tolcher

NEXT Oncology’s Dr. Anthony Tolcher Presents Data on Well-Tolerated Monotherapy
for Advanced and Metastatic Tumors at ESMO Congress 2022

DCC-3116 is a first-in-class inhibitor of autophagy. (SAN ANTONIO) September 16, 2022 –– Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, returned from the European Society for Medical Oncology (ESMO) in Paris, France, where he presented the findings of a phase I, first-in-human study that evaluates DCC-3116 alone and in combination with MAPK pathway inhibition in patients with MAPK …

Virginia Cancer Patient “Living with (Stage 4) Cancer” Thanks to Clinical Trial

Dr. Alexander I. Spira presented promising research findings at The American Societyof Clinical Oncology (ASCO) to help those with lung cancer. (FAIRFAX, VIRGINIA) June 27, 2022 –– Chuck Tonkin, 82, has been battling cancer since 2018. Now with stage 4 lung cancer, with metastatic disease to his brain, has found a new drug, adagrasib, that is giving him his life …

 NEXT Oncology Gives Patient Her Life Back with Clinical Trials 

P53, guardian of the genome, prevents solid tumor growth (SAN ANTONIO) June 10, 2022 –– Lindalou Trevino was the first patient to enroll in clinical trial PC14586, and because of her favorable response to this new investigational drug, she has renewed hope and a new lease on life. PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective …

NEXT Oncology Enrolls First Patient in Madrid Phase I Clinical Research Center 

New trial clinical trial is focused on novel therapy for triple negative breast cancer. (SAN ANTONIO) April 14, 2022 –– When NEXT Oncology expanded to Spain in late 2021, the goal was to increase global access to new cancer agents and anticancer therapies for patients with advanced cancer. NEXT Oncology – Madrid has enrolled its first patient in March 2022 …

NEXT Oncology Adds Dr. Sharon Wilks to Phase I Clinical Investigation Team

Wilks to focus on advancements in novel therapies for breast cancer (SAN ANTONIO) December 8, 2021 –– Medical oncologist Dr. Sharon Wilks joins NEXT Oncology bringing more than 30 years of research and clinical experience to the practice. NEXT Oncology’s Phase I oncology centers provide patients with advanced cancer access to the newest treatments available. Dr. Wilks focuses on research …

NEXT Oncology Partners with Spanish Hospital System to Open Two Phase I Clinical Centers

 New venture marks third and fourth site expansion in five months  (SAN ANTONIO) November 18, 2021 –– NEXT Oncology, founded by internationally known cancer researcher Dr. Anthony Tolcher, has entered into an agreement with the Quirónsalud Group to open two new phase I clinical trial centers in Spain. The venture increases global access to new agents and anticancer therapies for …